tbuckley/cabot-search huggingface dataset:
Bile acid-independent bile flow is differently regulated by glucagon and secretin in humans after orthotopic liver transplantation.
Authors: R Lenzen
Journal: Hepatology (1997)

The present study characterizes recovery of bile secretion after orthotopic liver transplantation (OLT) in humans with special regard to hormonal regulation of bile acid-independent bile flow by glucagon and secretin. Sixty-seven patients with an uncomplicated postoperative course were studied during the first 3 weeks after OLT to determine normalization of bile flow. A group of 7 and 10 patients, respectively, underwent a biliary stimulation test by either glucagon at days 7, 14, and 21 after OLT or by secretin at days 2, 10, and 21 after OLT. Secretin tests were similarly performed in patients with acute severe rejection during the first 10 days after OLT, while glucagon tests were performed in patients with acute allograft rejection occurring 2 weeks after OLT. Furthermore, hormone effects were studied in nontransplanted patients after cholecystectomy with indwelling biliary T tube. After OLT, bile secretory function recovered and stabilized within 14 days after surgery by reconstitution of both bile acid-dependent and -independent bile flow. Two weeks after OLT, bile secretion was comparable with nontransplanted patients after cholecystectomy. Glucagon and secretin stimulated bile acid-independent bile flow in transplanted and nontransplanted patients significantly, yet secretin choleresis, unlike glucagon choleresis, had already occurred during the first days after OLT and was unaffected by acute allograft rejection. These results allow the speculation that, in humans, glucagon and secretin exert their choleretic activity by different mechanisms and/or at different anatomical sites in the liver. Assuming that secretin acts at the bile duct cells, its secretory capacity was not altered by the transplantation procedure and during moderate or severe rejection episodes, as opposed to glucagon choleresis, which most likely originates in the hepatocytes and requires an entirely reconstituted canalicular transport system after OLT. (Hepatology 1997 Nov;26(5):1272-81)
Editor Journal of the American Medical Association
Authors: None D. H. B.
Journal: JAMA (1884)

February, 26, 1884. Notwithstanding it was distinctly announced by yourself at the June meeting of the Association of 1883, that permanent members of the Association could not vote, except they were there as elected and duly certified delegates, holding credentials from some one of the medical societies or associations known and recognized by the American Medical Association as legally organized bodies; there are some who still hold that a permanent member has an inherent right to an equal franchise with the certified delegates. In the 2nd section of the articles or plan of organization, adopted and embodied in the Transactions twenty-four years ago, we find the following, which I think should settle this point, both in principle and in practice. It reads thus: "Permanent members shall at all times be entitled to attend the meetings, and participate in the affairs of the Association, so long as they shall continue to
THE MEMBERSHIP LIST.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Family therapy helps addict
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion
Authors: Noemí Sevilla, Dorian B. McGavern, Chao Teng, Stefan Kunz, Michael B.A. Oldstone
Journal: Journal of Clinical Investigation (2004)

DCs play a pivotal role in bringing forth innate and adaptive immune responses. Viruses can specifically target DCs, rendering them ineffective in stimulating T cells, which can ultimately lead to immunosuppression. In the present study we have identified several potential mechanisms by which lymphocytic choriomeningitis virus (LCMV) induces immunosuppression in its natural murine host. The immunosuppressive LCMV variant clone 13 (Cl 13) infects DCs and interferes with their maturation and antigen-presenting capacity as evidenced by a significant reduction in the surface expression of MHC class I, MHC class II, CD40, CD80, and CD86 molecules. Additionally, Cl 13 infects hematopoietic progenitor cells both in vivo and in vitro, impairing their development. One mechanism by which hematopoietic progenitors are developmentally impaired is through the Cl 13–induced production of IFN-α and IFN-β (IFN-α/β). Mice deficient in the receptor for IFN-α/β show a normal differentiation of progenitors into DCs despite viral infection. Thus, a virus can evolve a strategy to boost its survival by preventing the maturation of DCs from infected progenitor cells and by reducing the expression of antigen-presenting and costimulatory molecules on developed DCs.
Swimming
Authors: Craig Sharp
Journal: British Journal of Sports Medicine (1994)

Just over 100 pages of text, with nearly 1000 references, is an excellent start, although such a good reference list could have been even more useful had it been arranged alphabetically, while still being defined by number in the text.The topic is research on nutrients as ergogenic aids and the author notes that 'peer-reviewed scientific journal articles have been misinterpreted, mis- quoted, misunderstood and misused to promote products'.The main division of the text is into the macronutrients and the micronutrients, with 16 pages devoted to the former, giving a good summary treat- ment to the whole of carbohydrates, proteins and fats, as well as fluid and electrolyte replacement.Sixty pages are devoted to a con- sideration of micronutrient sup- plementation, divided into chapters on the vitamins, the minerals (including zinc, selenium and chromium), the amino acids (arginine, aspartic acid, BCAAs, glutamate, glycine, lysine, ornithine and tryptophan) and 'meta- bolic intermediates' (alkalinizers, anti- oxidants, aspartate salts, carnitine, coenzyme Q10, creatine, inosine, ade- * reports on interdisciplinary investigations * reviews and updates on all aspects of physical therapy and the medical, surgical and therapy specialities relating to clinical practice * papers on the clinical, technical, epidemiological, educational and managerial aspects of practice * important news, reports, details of forthcoming events, book reviews and correspondence.
Urinary incontinence in elderly nursing home patients
Authors: J. G. Ouslander
Journal: JAMA (1982)

Among elderly nursing home patients, urinary incontinence is a prevalent and costly condition. In seven nursing homes studied, 419 (50%) of the elderly patients were incontinent of urine. Most had been incontinent at admission (64%), had more than one incontinent episode per day or a catheter (72%), and had concomitant fecal incontinence (64%). The majority of incontinent patients had substantial cognitive impairment and limitations in mobility. The severity of these impairments was related to the extent of incontinence. Complications such as urinary tract infection and skin breakdown occurred in almost 45% and were more common in patients with catheters. Physicians recorded incontinence as a problem, or any efforts to evaluate it, in the nursing home records of less than 15% of these patients. (<i>JAMA</i>1982;248:1194-1198)
Isolation of Pathogenic Fungus Cryptococcus Neoformans from Pigeon Droppings
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Research Exceptionalism
Authors: James Wilson, David Hunter
Journal: The American Journal of Bioethics (2010)

Research involving human subjects is much more stringently regulated than many other nonresearch activities that appear to be at least as risky. A number of prominent figures now argue that research is overregulated. We argue that the reasons typically offered to justify the present system of research regulation fail to show that research should be subject to more stringent regulation than other equally risky activities. However, there are three often overlooked reasons for thinking that research should be treated as a special case. First, research typically involves the imposition of risk on people who do not benefit from this risk imposition. Second, research depends on public trust. Third, the complexity of the moral decision making required favors ethics committees as a regulative solution for research.
Abstracts: Part V
Authors: F Bazzoll, S Gullini, R Zagari, P Pazzi, M Dalla Libera, P Pozzato, S Sottili, S Fossi, G Carli, R Scagliarini, P Simoni, E Cattedra, M Refik, Umit Ate, Ayhan Ding, Kenan Saglam, Tahir Unal, Selim Nalbant, Cihan Top, Fikri Kocabalkan, C Cicognani, M Malavolti, A Morselli-Labate, L Zamboni, R Talarico, C Sama, A Goren, M Soykan, Y Kir, A Uzun, H Beyler, G Qetinkaya, A Kadayifci, K Aydemir, M Arslan, B Sivri, S Aksoyek, G Kabak, B Kayhan
Journal: Gut (1995)

4th UEGWBerlin 1995 3.22 (mean ± SE) per mil). 3patients had a negative test at one week (excess Q 13C02 excretion = 1.5 ± 0.7 (mean ± SE) per mil) which however turned to be positive at the second week evaluation (excess v 13C02 excretion = 11.5 ± 2.8 (mean ± SE) per mil) Conclusions: 13C-UBT can assess Helicobac- ter pylori eradication as soon as one week after treatment withdraw.When performed at two weeks it shows the same sentivity and specificity of the test performed at four weeks after withdrawing medications.
Poetry
Authors: Jack Coulehan
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1158: Sudden Death in Children with Cardiomyopathy: Long Term Follow-Up from a National Population-Based Study of Childhood Cardiomyopathy
Authors: Tara Bharucha, Andrew M Davis, Christian Turner, Robert Justo, Terry Robertson, Jim Ramsay, Piers E Daubeney, Alan W Nugent, Ingrid King, Robert G Weintraub
Journal: Circulation (2008)

Introduction Better data regarding the incidence and risk factors for sudden cardiac death (SCD) in children with cardiomyopathy (CM) is critical in defining appropriate primary prevention strategies. Methods The National Australian Childhood Cardiomyopathy Study is a prospective cohort study, including all children in Australia with primary CM diagnosed at 0 – 10 years of age, between 1987–1997. SCD was defined as sudden and unexpected death in children who were not hospitalized and not in congestive heart failure at the time of death. Nine subjects with sudden death as presenting symptom were excluded. Indexed echocardiographic measurements at latest follow-up were compared between subjects with SCD and survivors. Results Study criteria were met by 291 children. Mean duration of follow-up was 9.2 years. The incidence of sudden death relative to each CM type, for all cases and as a proportion of deaths, is shown in the Table : Incidence of SCD by CM type. SCD incidence was significantly associated with CM type, for all cases ( p = 0.006) and when only those subjects who died were considered ( p = 0.005), with LVNC and RCM having up to 4 times the risk of other CM types. Children with familial DCM had a significantly higher rate of SCD than subjects with non-familial CM (12% vs 3%; p = 0.028), however, familial CM was not a risk factor in other CM types. DCM SCD subjects had larger LVEDd Z score than survivors (median 5.53 vs 1.16; p &lt;0.0001) and lower FS Z score (median −9.23 vs −0.51; p = 0.0025). HCM SCD subjects had thicker LVPW dimension Z scores than survivors (median 4.63 vs 1.18; p = 0.007). Twelve subjects (2 DCM, 8 HCM and 2 LVNC) underwent ICD implantation (8/12 for primary prevention). Conclusions: This population based study defines new risk factors for sudden death in children with CM. RCM is well known to have a high incidence of SCD. In addition, children with LVNC and those with DCM who have severe dilatation, systolic dysfunction or familial DCM are at increased risk of sudden death.
Myocardial Infarction Prognosis by Discriminating Analysis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bone metastases treated with immune checkpoint inhibitors: A single center experience.
Authors: Punita Grover, Vidhya Karivedu, Zheng Zhu, Roman Jandarov, Trisha Michel Wise-Draper
Journal: Journal of Clinical Oncology (2019)

e14105 Background: We conducted a retrospective study to analyze the overall survival (OS) and progression free survival (PFS) among patients with bone metastases (BMs) from Non Small Cell Lung Carcinoma (NSCLC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC) and others (including genitourinary carcinoma) treated with immunotherapy (Nivolumab, Pembrolizumab, Ipilimumab or a combination). Methods: We retrospectively evaluated patients with BMs treated at our institute from 2012-2017 who received either immunotherapy alone or in combination with other therapies for BMs including: medical therapy (zoledronic acid or denosumab), radiation or surgery. Univariate analysis was utilized to analyze OS and PFS. Results: A total of 58 patients were identified, median age at diagnosis of BMs was 61 years (range 29 – 94). 39 patients were male (67.2%) and 47(81%) patients had good performance status (KPS 70-100) at the time of immunotherapy initiation. The median time to diagnosis of BMs was 11.4 months. 20 patients had a single BM, 16 had 2-4 BMs and 22 had ≥5 BMs. Axial-only BMs were seen in 27 patients, appendicular-only in 8 and both in 23 patients. 40 patients were symptomatic and 28 patients had skeletal events (pathological fractures, spinal cord compression or hypercalcemia). 51 patients had other metastatic sites at the time of initiation of immunotherapy. 25 patients received nivolumab, 20 patients received pembrolizumab and 4 patients received combination immunotherapy. 41 patients received additional treatments for BMs. The median OS from the start of immunotherapy was 5.15 months and median PFS was 3 months. On univariate analysis male sex (p = 0.03) and combination immunotherapy (p = 0.06) were associated with better OS. Patients who received additional treatments for BMs (p = 0.04) and combination immunotherapy (p = 0.02) had better PFS. Conclusions: Combination immunotherapy and use of additional treatment modalities for BMs is associated with better survival. Further analysis is required to validate these results. [Table: see text]
Reply to Gianluca Giannarini, Vincenzo Ficarra, and Claudio Valotto’s Letter to the Editor re: Stephen B. Williams, Marcus G.K. Cumberbatch, Ashish M. Kamat, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.039
Authors: Stephen B. Williams, Ibrahim Jubber, James W.F. Catto, Siamak Daneshmand
Journal: European Urology (2020)
QOLP-01. EFFECTS OF TUMOR TREATING FIELDS ON HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN NEWLY DIAGNOSED GLIOBLASTOMA: AN EXPLORATORY ANALYSIS OF THE EF-14 RANDOMIZED PHASE III TRIAL
Authors: Tobias Walbert, Gitit Lavy-Shahaf
Journal: Neuro-Oncology (2018)

Tumor Treating Fields (TTFields) are a novel treatment modality that continuously delivers alternating electric fields to the tumor region. TTFields interfere with the assembly of the mitotic spindle leading to apoptosis. In the EF-14 phase III study in newly diagnosed glioblastoma, TTFields plus temozolomide (TTFields/TMZ) showed significant increase in overall and 5-year survival rates compared to temozolomide. TTFields/TMZ did not negatively impact nine prespecified HRQoL scales (global health, physical, cognitive, role, social and emotional functioning, itchy skin, pain, and leg weakness) except for increased itchy skin. We present an exploratory analysis of the remaining 17 EORTC QLQ C-30 and BN-20 HRQoL scales. HRQoL was measured by the EORTC QLQ-C30 and BN20 questionnaires at baseline and every 3 months thereafter. Mean changes from baseline as well as significant changes in scores over time (>10 points) were evaluated using a repeated measures test. Deterioration-free survival and time-to-deterioration in HRQoL were assessed for each scale, as well as % patients with stable/improved HRQoL versus baseline. No statistically or clinically significant decline in any of the exploratory HRQoL scales was seen in the repeated measures analysis or in time to deterioration. Significantly more patients treated with TTFields/TMZ versus TMZ reported stable/improved bladder control (63.6% versus 46.8%, p=0.001) and diarrhea (60.6% versus 43.7%, p=0.001) compared to baseline. The deterioration-free survival for diarrhea, future uncertainty and headaches was significantly delayed in TTFields/TMZ treated patients compared to TMZ alone (HR 0.68, 0.71 and 0.67, respectively, p<0.001). CONCLUSIONS: No negative impact of HRQoL was seen in any of the exploratory scales between patients treated with temozolomide only or TTFields and TMZ. Adding TTFields to standard therapy in newly diagnosed glioblastoma does not appear to negatively impact QoL.
A Convulsant Agent for Psychiatric Use
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal